As a consequence, CADD522 treatment could result in an increase of RUNX1 and/or RUNX2 to compensate for the functional loss of RUNX2, which is normally necessary to mediate BC growth, survival or metastasis. This evidence concerns the gene RUNX2 and breast cancer.